Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Bidard, François‐Clément; Kaklamani, Virginia; Neven, Patrick; Streich, Guillermo; J. Montero, Alberto; Forget, Frédéric; Mouret‐Reynier, Marie‐Ange; Sohn, Joohyuk; Taylor, Donatienne; Harnden, Kathleen; T. Khong, Hung; Kocsis, Judit; Dalenc, Florence; M. Dillon, Patrick; Babu, Sunil; Waters, Simon; Deleu, Ines; Á. García-Sáenz, José; Bria, Emilio; Elena Cazzaniga, Marina; Lu, Janice; Aftimos, Philippe; Cortés, Javier; Liu, Shubin; Tonini, Giulia; Laurent, Dirk; Habboubi, Nassir; G. Conlan, Maureen; Bardia, Aditya

doi:10.1200/jco.22.00338

Public

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Published in Journal of Clinical Oncology • May 18, 2022

Authors:

François‐Clément Bidard

Virginia Kaklamani

Patrick Neven

Abstract

PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis. Elacestrant is a novel, oral selective ER degrader that demonstrated activity in early studies. METHODS This randomized, open-label, p...

Subject

Medicine

Internal medicine

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!